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Background Gastro-oesophageal reflux disease (GORD) is a frequently occurring disease that may be considered 
a public health issue, particularly in developed countries. The specificity of heartburn for the diagnosis of GORD 
is good. Our aim was to define the prevalence of heartburn in Belgium, characterizing both its impact on 
everyday life and the ensuing use of medical resources. 
Methods Two thousand people living in Belgium, selected randomly after stratification, were interviewed face to 
face. The main question in the questionnaire used in this interview concerned the presence over the previous 12 
months of a burning sensation in the epigastric and/or retrosternal region. This was followed by 21 secondary 
questions on the characteristics of the population studied, the impact of heartburn on everyday life, and the 
medical resources used. 
Results Twenty-eight per cent of the population interviewed reported heartburn. This symptom was present at 
least once a week In 42% of sufferers. Heartburn was more frequent in women than men (P < 0.05) and was not 
distributed uniformly throughout the various regions of the country (P < 0.05). Seventy-seven per cent of the 
people with heartburn found that it had a significantly negative impact on their daily lives (in 27%, this effect 
was strong). Heartburn associated with a substantial negative impact on daily life was characterized by a higher 
frequency of symptoms (P < 0.0001 ), a longer duration of the problem (P = 0.006), and the presence of pain (P 
< 0.0001) and anxiety (P < 0.0001). Fifty-six percent of individuals with heartburn had already sought medical 
advice, 45% had undergone an upper-gastrointestinal tract endoscopy, and 59% were taking medications. Among 
patients complaining that heartburn had a substantial negative effect on their everyday lives, 21.6% had not 
sought medical advice and 22.2% did not take any medication. 
Conclusion Heartburn is very frequent in Belgium and is associated with a considerable negative impact on 
everyday life. It also generates a significant use of medical resources. However, among the patients complaining 
of a substantial negative effect on their daily lives, one-fifth (which would represent 1.5% of the Belgian 
population) seemed to lack appropriate care. 
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Introduction 
Gastro-oesophageal reflux, under certain conditions, is a physiological phenomenon in man. To define 
pathological gastro-oesophageal reflux disease (GORD) is not as easy as it may seem at first sight. Pathology 
may be considered to be present when the acid reflux is quantitatively abnormal, when oesophageal lesions are 
observed, or simply because indicative symptoms are present. From the patient's point of view, as soon as there 
are symptoms, the phenomenon may be considered pathological. 
These symptoms may have repercussions on the quality of life [1,2] and may require the use of medical 
resources [3,4]. GORD is therefore not only an individual problem but also a public health issue. During recent 
decades, two parallel (and probably related) events have occurred: (1) the development of drugs that are very 
effective in the management of GORD symptoms and lesions, and (2) a dramatic increase in the number of 
people suffering from GORD and therefore requiring medical advice and treatment. These combined phenomena 
have generated a significant increase in the cost of the medical management of GORD in Western countries [5]. 
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In many European countries, consensus conferences have been held and guidelines published [6,7] in order to 
define reasonable and affordable strategies for the management of this disease. To comply with local medical 
realities, these strategies must take the specificities of local epidemiology into account as well as the way the 
disease is coped with by local populations. Very few European epidemiological data are available [3,8-11], and 
only one Belgian study has been published in abstract form [12]. In the European studies, the prevalence of 
gastro-oesophageal reflux symptoms, mainly heartburn, ranges from 18 to 30%. In Belgium, in a telephone-call 
study carried out on a representative sample of 3000 individuals aged over 35 years [12], 28.1% experienced 
heartburn during the previous 12 months, 11.3% at least once a week, and 4.1% daily. The aim of the present 
study was to evaluate the prevalence of GORD symptoms in the Belgian population and their impact on daily 
life and the utilization of medical resources. 
Method 
Between 10 December and 24 December 1998, 2000 people living in Belgium were questioned about heartburn. 
They had been selected randomly from the entire population (8359 200) of people aged over 15 years. To 
provide a sample representative of the country, the selection was stratified for the 11 Belgian provinces on the 
basis of degree of urbanization (four degrees, from big cities to rural areas), sex, age, profession and socio-
economic level. 
The selection of individuals was performed at random as follows. The country was divided into 34 entities based 
on 11 provinces and four degrees of urbanization. Inside these entities, a series of municipalities were chosen at 
random. Up to five interviews were performed in each municipality according to its size. In each municipality, 
habitations were selected at random for these interviews by a computer program choosing streets and numbers of 
these habitations by groups of ten interviews. 
The randomly selected individuals were interviewed face co face at their homes for a maximum of 30 min by 
professionals not involved in healthcare: these interviewing professionals were agents from the Belgian INRA 
company specializing in omnibus face-to-face interviews. It would be impossible to publish the complete 
questionnaire as part of the paper. However, an English translation was submitted, together with the present 
paper, for peer reviewing and is available with the electronic version of the paper. The following is a short 
summary of its contents. 
The questionnaire included one primary question and 21 secondary questions, with one to ten sub-questions. The 
primary question was about the presence or absence over the previous 12 months of a burning sensation in the 
epigastric or retrosternal region. It also asked whether this sensation ascended in the retrosternal region and 
whether, in the absence of such a symptom, the individual had been treated with medications or had undergone 
surgery. After this primary question, the complete interview was carried out only with those individuals who had 
experienced the burning sensation over the previous 12 months. The subsequent questions concerned the words 
used by the subjects to define their symptoms, the frequency of complaints, their duration from the onset of the 
problem, and possible favouring circumstances. The impact on everyday life and possible anxiety induced by the 
problem, as well as lifestyle changes, were also looked at. Questions were asked concerning the use of medical 
resources, including medical consulting and follow-up, advice from the pharmacist, upper-gastrointestinal tract 
endoscopy, drug treatment, and information about the surgical option. Potential risk factors, including family 
history, smoking habits, alcohol consumption, medications taken, stress, and body mass index (BMI) 
calculations, were recorded. 
The consistency and completeness of the questionnaire were checked afterwards for each interview. The sample 
was representative when compared with the data provided by the National Institute for Statistics. 
Statistics 
The 2000 individuals interviewed can be considered as a representative sample of the whole Belgian population. 
The results are given with their 95% confidence intervals. To compare results of defined subgroups of 
individuals, we used Student's t-test or the chi-squared test as required. 
Results 
Prevalence of heartburn 
Of the 2000 individuals interviewed, 568 (28.4%, 95% CI 26.4-30.4%) had experienced heartburn during the 
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previous 12 months. An additional 1.2% had experienced it previous to this period but were symptom-free under 
medical treatment or after surgery. Heartburn was significantly more frequent in women (31.1%, 95% CI 28.2-
34%) than men (25.6%, 95% CI 23.1-28.1%; P < 0.05). Prevalence of heartburn also varied in different parts of 
the country: it was more frequent in Wallonia (south-east) (41.4%, 95% CI 37.6-45.2%) than in Brussels (centre) 
(28.1%, 95% CI 22.3-33.9%) or Flanders (north-west) (20.9%, 95% CI 18.5-23.3%; P < 0.05). There were no 
significant differences according to age (15-34 years: 27.5%, 95% CI 24.2-30.8%; 35-54 years: 28.8%, 95% CI 
25.3-32.3%; > 54 years: 28.7%, 95% CI 25.2-32.4%) social level (high: 25.9%, 95% CI 22-29.8%; middle-high: 
28.8%, 95% CI 24.9-32.7%; middle-low: 27.9%, 95% CI 24-31.8%; low: 30.8%, 95% CI 26.7-34.9%), or 
urbanization (cities: 25.8%, 95% CI 22.1-29.5%; towns: 29.2%, 95% CI 26.2-32.2%; rural areas: 29.5%, 95% CI 
25.8-33.2%). 
Among the individuals complaining of heartburn, 14% (95% CI 11.1-16.9%) had experienced it for less than 1 
year, 25% (95% CI 21.4-28.6%) for 1-3 years, and 51% (95% CI 46.9-55.1%) for more than 3 years (10% no 
information available). The frequency of symptoms among refluxers was at least once a day in 15% (95% CI 
12.1-17.9%), at least once a week in 27% (95% CI 23.3-30.7%), at least once a month in 23% (95% CI 19.5-
26.5%), and less than once a month in 32% (95% CI 28.2-35.8%) (3% no data available). Ninety-five per cent 
(95% CI 93.2-96.8%) of people could mention particular circumstances for the appearance of symptoms, 
including after certain meals (42%, 95% CI 37.9-46.1%) and stressful contexts (35%, 95% CI 31.1-38.9%). 
Impact on everyday life 
Heartburn was considered as hampering everyday life in 77% (95% CI 73.5-80.5%) of cases. This interference 
was reported as strong in 27% (95% CI 23.3-30.7%) of cases. Aspects of daily life that were the most hampered 
by heartburn were family life (49%, 95% CI 44.9-53.1%), social life (30%, 95% CI 26.2-33.8%), leisure time 
(26%, 95% CI 22.4-29.6%). and professional life (24%, 95% CI 20.5-27.5%). In patients for whom the 
interference with daily life was considerable (n = 153), symptoms were significantly more frequent (at least once 
a week: 57.9%, 95% CI 50.1-65.7% v. 19.7%, 95% CI 12.8-26.6%; P < 0.0001) and had been present for a 
longer period of time (> 1 year: 79.7%, 95% CI 73.3-86.1% υ. 64.3%, 95% CI 55.9-72.7%; P = 0.006), and 
heartburn was associated with a sensation of pain more often (57.2%, 95% CI 49.4-65% υ. 9%, 95% CI 4-14%: 
P < 0.0001) and generated anxiety more often (26.7%, 95% CI 19.8-33.6% υ. 0.8%, 95% CI 0-2.4%; P < 
0.0001) than in patients whose daily lives were unaffected. 
Risk factors in patients for whom heartburn has a strong negative effect on daily life 
Among the subjects complaining of heartburn over the previous year, 29% (95% CI 25.3-32.7%) had a family 
history of gastric or oesophageal disease, 34% (95% CI 31.1-37.9%)  were  smokers  (one-third smoked  more 
than 20 cigarettes/day), 44% (95% CI 39.9-48.1%) drank alcohol (one-quarter drank more than 10 units/ week), 
25% (95% CI 21.4-28.6%) took medications for other diseases (including antihypertensives (6.5%), antiangina 
pectoris drugs (5.2%), analgesics (4.6%), anti-inflammatory drugs (2.0%), antidepressants (3.9%), anxiolytics 
(5.9%), and bronchospasmolytic agents (5.9%)), 46% (95% CI 41.9-50.1%) had a BMI greater than 25 (one-fifth 
> 30), and 58% (95% CI 53.9-62.1%) had a stressful life. As shown in Table 1, some of these risk factors were 
more frequent in subjects whose heartburn interfered seriously with their daily lives. 
 
Table 1.  Prevalence of risk factors (% with 95% CI) In subjects with heartburn according to Impact on daily life 
Risk factor Severe effect (a)  
(n = 163) 
Slight effect (b)  
(n = 288) 
No effect (c)  
(n = 128) 
Positive family history 37.3 (29.6-45) 30.6 (25.3-35.8) 15.9 (9.5-22.3)*** 
Smoker 41.2 (33.4-49) 28.8 (23.6-34) 35.7 (27.3-44.1) 
Heavy smoker (> 20 cigarettes/day) 18.3 (12.2-24.4) 12.2 (8.4-166) 7.1 (2.6-11.6)** 
Alcohol drinkers 38.6 (32.6-44.7) 42.7 (37-4β.4) 52.4 (44.8-60)* 
> 10 units alcohol/week 15 (9.3-20.7) 8 (4.9-11.1) 10.3 (5-156) 
Drugs for other illnesses 33.3 (25.8-40.8) 29.2 (23.9-34.5) 8.7 (3.8-13.8)*** 
BMI > 30 15 (10.8-19.4) 9 (5.7-12.3) 7.1 (3.7-10.5)* 
Stressful life 66 (59.5-72.5) 54.5 (48.7-60.3) 50.8 (43.1 -58.5)** 
* P < 0.05 compared with (a); ** P < 0.01 compared with (a): *** P < 0.0001 compared with (a). 
 
Published in:  European Journal of Gastroenterology (2002), vol. 14, pp. 279-284 
Status : Postprint (Author’s version) 
 
Utilization of medical resources 
Among the subjects complaining of heartburn, 56% (95% CI 51.9-60.1%) had already consulted a physician for 
the problem (half of them having been followed up). Eighteen per cent (95% CI 14.8-21.2%) had asked for 
advice from a pharmacist, 45% (95% CI 40.9-49.1%) had undergone an upper-gastrointestinal tract endoscopy, 
48% (95% CI 44.9-52.1%) had changed their lifestyles, and 59% (95% CI 55-63%) took medications, including 
antacids (44%), H2-blockers (7.8%), prokinetics (7.6%) and proton-pump inhibitors (PPIs; 6.3%). As shown in 
Table 2, resorting to medical aid was significantly higher in those who considered that their heartburn seriously 
hampered their daily lives. However, in this subgroup of individuals, 21.6% (95% CI 15.1-28.1%) had not 
sought medical advice and 22.2% (95% CI 15.5-28.9%) did not take any medication. Overall, among the 
individuals who took medication, 93% (95% CI 90.5-95.5%) were satisfied with their treatment. 
 
Table 2.  Utilization of medical resources (% with 95% CI) in subjects with heartburn according to impact on 
dally life 
Medical resource Severe effect (a)  
(n  = 153) 
Slight effect (b)  
(n = 288) 
No effect (c) 
(n = 128) 
Visit to physician 78.4 (71.9-84.9! 54.6 (46.7-62.4) 30.2 (22.2-38.2)* 
Medical follow-up 49.7 (413-87.6) 21.9 (17.1-26.7) 10.3 (5-15.6)** 
Pharmacist advice 24.8 (16-31.6) 19.1 (14.8-23.6) 7.9 (3.2-12.6)* 
Upper-GI endoscopy 54.9 (47-62.8) 29.2 (23.9-34.5) 15.9 (9.5-22.3)** 
Several endoscopies 25.5 (18.6-32.4) 14.6 (10.5-18.7) 10.3 (5-15.6)* 
Lifestyle modifications 65.4 (57.9-72.9) 46.9 (41.1-52.7) 32.5 (24.3-42.7)** 
Medication for GORD*** 77.8 (71.2-84.4) 56.6 (50.9-62.3) 41.3 (32.7-49.9)** 
Antacids 52.3 (44.4-60.2) 47.2 (41.4-53) 29.4 (21.4-37.4)** 
H2-blockers 15 (9.3-20.7) 5.2 (2.6-7.8) 4.8 (1.1-8.5)* 
PPIs 9.8 (5.1-14.5) 4.2 (1.9-8.5) 7.1 (2.6-11.6) 
Prokinetics 17.8 (11.6-23.8) 5.6 (2.9-8.3) 0** 
Other 15 (8.4-21.6) 4.2 (1.6-6.8) 0.8 (0-2.4)** 
GI, gastrointestinal; GORD, gastro-oesophageal reflux disease; PPI, proton-pump inhibitors. 
*P < 0.01 compared with (a); **P< 0.001 compared with (a); ***some patients take several medications. 
 
Discussion 
Our study shows that in Belgium, symptoms indicating gastro-oesophageal reflux have a prevalence comparable 
to that reported in other European countries. In recent studies carried out in Finland [8], Sweden [9], France [3] 
and the UK [11], symptoms of gastro-oesophageal reflux were present in 30%, 25%, 27.1% and 18% of the 
populations, respectively. Regional differences may exist, but the choice of the symptom to characterize GORD 
and phrasing of the questionnaire are crucial and might explain some of these differences. In previous studies, 
various symptoms have been used, including epigastric pain, acid regurgitation and heartburn. Among these, 
heartburn has the highest specificity and sensitivity for the diagnosis of gastro-oesophageal reflux [13]. The 
specificity is probably optimal when heartburn is defined as a burning sensation starting in the epigastric or low 
retrosternal region and spreading upwards [13]. In the present study, 455/569 subjects complaining of heartburn 
described it as a sensation spreading upwards in the retrosternal region. Methodological differences may also 
explain variations in the results. However, although the previous study carried out in Belgium used a different 
method for data collection (telephone calls), it produced an almost identical result: 28% of individuals 
complaining of heartburn during the previous year [12]. 
While using the same definition for the symptoms and the same methodology in each case, our study shows that 
striking differences may exist between populations that arc very close geographically. It is of interest that the 
difference we found between the three regions of Belgium (Wallonia, Brussels, Flanders) had already been 
found, in almost exactly the same proportions, in the previous Belgian epidemiological study [12]. Differences in 
gastro-oesophageal reflux or heartburn prevalence between various populations have often been explained by 
lifestyle and other risk factors. The high prevalence of heartburn found among North Americans, for example, 
with 4-7% having heartburn daily [14,15], 14-30% weekly [14,15] and 15-44% monthly [14,16], has been 
correlated to obesity and a particular diet. In the population with heartburn in the present study (data given in a 
separate part of the study), a positive family history, concomitant taking of medication for other diseases, 
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including antihypertensives, anti-anginals and nonsteroidal anti-inflammatory drugs, together with a stressful 
lifestyle was more frequent in Wallonia than Flanders, while no differences were found for smoking habits, 
alcohol consumption or excess weight [17]. We also found a significant difference in the prevalence of heartburn 
between men and women. Heartburn was more frequent in women. This is in accordance with a French 
epidemiological study [3], but in other studies this frequency was either equal [9,16] or higher in men [18,19]. In 
our population, risk factors, including positive family history, concomitant taking of medication, stressful 
lifestyle and excess weight, were more frequent among women (data not shown). 
It is the intensity and consequences for everyday life, rather than simply the presence of a symptom indicating 
gastro-oesophageal reflux, such as heartburn, that determine the burden for the individual and the community. In 
this respect, we should emphasize that, in our study, 77% of individuals complaining of heartburn also 
complained of a significantly negative effect on their daily lives. It has been shown in previous studies that 
gastro-oesophageal reflux impairs the quality of life substantially [1,2,20,21]. In the population complaining of 
heartburn in this study (which represents, by extrapolation, almost 30% of the whole population of the country), 
a large proportion (27%) reported severe disruption of their daily lives. Therefore, up to 10% of the Belgian 
population may be severely hampered in everyday life by heartburn. It must be emphasized that, in the present 
work, we did not use a strict quality-of-life measurement but rather a general appreciation by the patient. Strict 
evaluation of quality of life by validated questionnaires may give substantially different results. This may also be 
the reason why the proportion of subjects with severe impairment of daily life may seem higher than expected. 
Previous studies have shown that, in gastro-oesophageal reflux, impairment of quality of life was related more to 
the intensity of heartburn than to the presence of oesophagitis [1,22]. In this work, hampering of daily life by 
heartburn was associated with a high frequency of episodes, a painful sensation, and the anxiety that was 
generated. This may be compared with an earlier American study in which the quality-of-life impairment due to 
GORD was noted mainly in the pain and psychological health sections of the questionnaire used (SF36) [2,21]. 
Considering the potential impact of severe heartburn on the individual's quality of life and the burden for the 
community, it seems useful to give the risk factors for severe heartburn. In the population for this study, 
individuals with a positive family history of gastric or oesophageal diseases, taking medication for other 
illnesses, having stressful lives, smoking heavily and being overweight (BMI > 30) were at higher risk. In a 
recent study, it was shown that, on the whole, GORD was not more frequent in individuals with a positive family 
history of GORD, except in cases of severe lesions associated with reflux, such as Barrett's oesophagus or 
oesophageal adenocarcinoma [19]. Our data show that not only the objective but also the subjective severity of 
GORD, assessed here by the impact of heartburn on everyday life, may be associated with a family history and 
therefore genetic and/or environmental influences. Another explanation for this familial influence could be the 
childhood training phenomenon, as described by some authors in irritable bowel syndrome [23]. Treatment with 
antihypertensives, antianginals and bronchospasmolytics, which may favour reflux [24], was found more often in 
individuals complaining of severe heartburn. However, these drugs are often essential for the patient, and little 
can be done with regard to them. Stress, smoking and excess weight are part of the lifestyle classically associated 
with GORD or its symptoms [25]. According to our data, these factors also seem to influence the subjective 
severity of GORD. Information from the patients regarding this point should certainly be part of their overall 
management. In previous studies, alcohol consumption was not associated with the symptoms of GORD [9]. In 
the population in this study, a mild alcohol intake (< 10 units/week) was associated with less hampering of 
everyday life by heartburn. The reason for this remains unclear to us and confounding factors may have been 
involved. 
Considering its frequency and the expense of diagnostic procedures and treatment, GORD is the cause of a lot of 
individual and social cost in Western countries. Not surprisingly, our data showed that the subjective severity of 
the symptoms was correlated with the utilization of medical resources. A few points need to be discussed here. 
Firstly, in the present population, a rather large proportion of individuals had undergone upper-gastrointestinal 
tract endoscopy. This would certainly result in significant costs, which, however, do remain reasonable in 
Belgium (endoscopy fees range from €100 to €150, much lower than in the USA). Moreover, endoscopy has a 
reassuring effect in about two-thirds of the patients (data not shown), as confirmed recently by a Danish group 
working with dyspeptic patients [26]. 
Considering the potential influence of anxiety (shown by our own data) on the severity of the effect of heartburn 
on daily life, the cost of an early endoscopy must be balanced against its potentially positive effect on subsequent 
quality of life. Prospective studies could be valuable in evaluating these parameters correctly. Secondly, while 
numerous patients complained of significant or even severe heartburn, more than 90% of those being treated 
were satisfied with their treatment. The majority of the patients rely on simple and cheap treatments, such as 
antacids, indicating that in most cases the use of more potent drugs (which are also more expensive) is probably 
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not necessary. The presence of a small number of unsatisfied patients, however, indicates that some are still 
treated inadequately and that an effort must be made to tailor treatment to the complaints of the patients. 
Finally, as far as symptomatic gastro-oesophageal reflux is concerned, good care and management would seem 
to imply a compromise between the best possible correction of quality-of-life impairment on the one hand and 
reasonable and affordable costs on the other. It should be emphasized that, of the individuals in this study who 
complained that heartburn caused severe disturbance to their daily life, one-fifth had never sought any medical 
advice and one-fifth did not take any treatment (not even over-the-counter antacids). The use of these simple and 
inexpensive palliatives should be encouraged for those who seem to lack appropriate care and who may represent 
up to 1.5% of the Belgian population. 
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